TABLE 1

Effect on islet allograft survival of adoptive transfer of alloMHC peptide–pulsed myeloid self-DCs

GroupImmunosuppression (intraperitoneal ALS on day −7)Inoculation of P5-pulsed self-DCs (route)Islet donorSurvival time (days)MST ± SD (days)
IWF7, 7, 8, 8, 8, 87.7 ± 0.5
IIBN7, 8, 8, 8, 8, 98.0 ± 0.6
III0.5 mlWF11, 12, 14, 16, 1814.2 ± 2.8
IV0.5 mlBN12, 13, 14, 15, 1514.3 ± 1.3
V0.5 ml106 P5-pulsed DC (i.t.)WF72, 58, >200 (9 animals)>200
VI0.5 ml106 P5-pulsed DC (i.t.)BN14, 15, 15, 1615.0 ± 0.8
VII106 P5-pulsed DC (i.v.)WF11, 12, 13, 11, 1612.6 ± 2.1
VIII2 × 106 P5-pulsed DC (i.v.)WF12, 12, 14, 1613.5 ± 2.3
IX0.5 ml2 × 106 P5-pulsed DC (i.v.)WF25, >200 (4 animals)>200
X0.5 ml2 × 106 P5-pulsed DC (i.v.)BN13, 14, 15, 1614.5 ± 1.3
  • ACI recipients were pretreated with intrathymic (i.t.) injection of 1 × 106 P5-pulsed myeloid self-DCs (groups V and VI) or intravenous (i.v.) injection of P5-pulsed myeloid self-DCs (groups VII, VIII, IX, and X) with or without intraperitoneal 0.5 ml ALS 7 days before intraportal injection of 1,200–1,500 WF (donor) or BN (third party) islets.